dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Camacho‑Toledano, Celia |
dc.contributor.author | Machín Díaz, Isabel |
dc.contributor.author | Calahorra Melero, L. |
dc.contributor.author | Cabañas‑Cotillas, María |
dc.contributor.author | Otaegui, David |
dc.contributor.author | Midaglia Fernandez, Luciana |
dc.contributor.author | Castillo-Trivino, Tamara |
dc.contributor.author | Comabella Lopez, Manuel |
dc.date.accessioned | 2022-12-02T08:20:28Z |
dc.date.available | 2022-12-02T08:20:28Z |
dc.date.issued | 2022-11-19 |
dc.identifier.citation | Camacho-Toledano C, Machín-Díaz I, Calahorra L, Cabañas-Cotillas M, Otaegui D, Castillo-Triviño T, et al. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis. J Neuroinflammation. 2022 Nov 19;19:277. |
dc.identifier.issn | 1742-2094 |
dc.identifier.uri | https://hdl.handle.net/11351/8573 |
dc.description | Medicina personalitzada; Contestador i no contestador |
dc.description.sponsorship | This work was supported by the Instituto de Salud Carlos III (PI18/00357, RD16-0015/0019, PI21/00302, all co-funded by the European Union), the Fundación Merck Salud (FMS_2020_MS), Esclerosis Múltiple España (REEM-EME-S5 and REEM-EME_2018), ADEMTO, ATORDEM and AELEM. CC-T holds a predoctoral fellowship from the Instituto de Salud Carlos III (FI19/00132, co-funded by the European Union). LC and JG-A were hired under PI18/00357 and RD16/0015/0019, respectively. DC, MCO and IM-D were hired by SESCAM. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Journal of Neuroinflammation;19 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Marcadors bioquímics |
dc.subject | Immunosupressió |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Myeloid-Derived Suppressor Cells |
dc.subject.mesh | Biomarkers |
dc.title | Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s12974-022-02635-3 |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | células supresoras de origen mieloide |
dc.subject.decs | biomarcadores |
dc.relation.publishversion | https://doi.org/10.1186/s12974-022-02635-3 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Camacho-Toledano C, Machín-Díaz I, Calahorra L, Cabañas-Cotillas M] Neuroimmuno Repair Group, Hospital Nacional de Parapléjicos-SESCAM, Toledo, Spain. [Otaegui D] Multiple Sclerosis Unit, Biodonostia Health Institute, San Sebastián, Spain. [Castillo-Triviño T] Multiple Sclerosis Unit, Biodonostia Health Institute, San Sebastián, Spain. Neurology Department, Hospital Universitario Donostia, San Sebastián, Spain. [Comabella M, Midaglia L] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 36403026 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |